Related Experiment Videos
[Thromboxane A2 synthetase inhibitor in asthma therapy]
K Machida1, K Takagi, M Horiba
12nd Department of Internal Medicine, Nagoya University School of Medicine.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|November 1, 1996
Summary
Thromboxane A2 (TXA2) contributes to asthma. Inhibiting TXA2 synthetase with ozagrel hydrochloride effectively reduced asthma symptoms and steroid use, offering a new therapeutic option.
Area of Science:
- Biochemistry
- Pharmacology
- Pulmonology
Context:
- Thromboxane A2 (TXA2), a potent platelet aggregator and vasoconstrictor, plays a significant role in mediating bronchial asthma.
- TXA2 exacerbates asthma by inducing airway smooth muscle contraction and promoting airway hyperresponsiveness.
Purpose:
- To review the role of TXA2 synthetase inhibitors in current asthma therapy, particularly ozagrel hydrochloride.
- To discuss the efficacy of TXA2 inhibition based on the Japanese guideline for allergic disorders.
Summary:
- Ozagrel hydrochloride, a specific TXA2 synthetase inhibitor, demonstrated significant efficacy in a Phase III study for ameliorating asthma symptoms.
- Clinical trials showed that ozagrel hydrochloride reduced the need for concomitant steroid therapy compared to azelastine hydrochloride.
- Both basic and clinical research confirm the effectiveness of TXA2 synthetase inhibitors in managing airway hyperresponsiveness.
Impact:
- TXA2 synthetase inhibitors represent a promising therapeutic strategy for asthma management.
- Ozagrel hydrochloride offers a potential alternative or adjunct to existing asthma treatments, potentially reducing steroid dependency.
- This review highlights the importance of targeting the TXA2 pathway in developing novel antiasthmatic agents.